SE9201239D0 - Agents for treating substance abuse disorders - Google Patents

Agents for treating substance abuse disorders

Info

Publication number
SE9201239D0
SE9201239D0 SE9201239A SE9201239A SE9201239D0 SE 9201239 D0 SE9201239 D0 SE 9201239D0 SE 9201239 A SE9201239 A SE 9201239A SE 9201239 A SE9201239 A SE 9201239A SE 9201239 D0 SE9201239 D0 SE 9201239D0
Authority
SE
Sweden
Prior art keywords
pct
abuse
agents
substance abuse
abuse disorders
Prior art date
Application number
SE9201239A
Other languages
English (en)
Swedish (sv)
Inventor
A Bjoerk
Original Assignee
Kabi Pharmacia Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kabi Pharmacia Ab filed Critical Kabi Pharmacia Ab
Priority to SE9201239A priority Critical patent/SE9201239D0/xx
Publication of SE9201239D0 publication Critical patent/SE9201239D0/xx
Priority to US08/325,212 priority patent/US5565455A/en
Priority to IL105449A priority patent/IL105449A/en
Priority to AT93911554T priority patent/ATE184484T1/de
Priority to DK93911554T priority patent/DK0637242T3/da
Priority to BR9306361A priority patent/BR9306361A/pt
Priority to AU40437/93A priority patent/AU659941B2/en
Priority to CA002118512A priority patent/CA2118512C/en
Priority to JP51825193A priority patent/JP3245642B2/ja
Priority to RO94-01692A priority patent/RO117150B1/ro
Priority to PCT/SE1993/000339 priority patent/WO1993020821A1/en
Priority to CZ942606A priority patent/CZ281296B6/cs
Priority to DE69326459T priority patent/DE69326459T2/de
Priority to HU9403020A priority patent/HU223463B1/hu
Priority to ES93911554T priority patent/ES2139007T3/es
Priority to SK1269-94A priority patent/SK279940B6/sk
Priority to RU94045866A priority patent/RU2126254C1/ru
Priority to UA94105949A priority patent/UA27884C2/uk
Priority to EP93911554A priority patent/EP0637242B1/en
Priority to ZA932757A priority patent/ZA932757B/xx
Priority to PH46084A priority patent/PH31051A/en
Priority to BG99129A priority patent/BG62154B1/bg
Priority to NO943977A priority patent/NO308827B1/no
Priority to KR1019940703758A priority patent/KR100321319B1/ko
Priority to EE9400398A priority patent/EE02974B1/xx
Priority to GR990403117T priority patent/GR3032030T3/el
Priority to NO20004169A priority patent/NO318461B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
SE9201239A 1992-04-21 1992-04-21 Agents for treating substance abuse disorders SE9201239D0 (sv)

Priority Applications (27)

Application Number Priority Date Filing Date Title
SE9201239A SE9201239D0 (sv) 1992-04-21 1992-04-21 Agents for treating substance abuse disorders
EP93911554A EP0637242B1 (en) 1992-04-21 1993-04-19 Agents for treating substance abuse disorders
DE69326459T DE69326459T2 (de) 1992-04-21 1993-04-19 Wirkstoffe zur behandlung von suchterkrankungen
ES93911554T ES2139007T3 (es) 1992-04-21 1993-04-19 Agentes para el tratamiento de trastornos derivados del abuso de drogas.
AT93911554T ATE184484T1 (de) 1992-04-21 1993-04-19 Wirkstoffe zur behandlung von suchterkrankungen
DK93911554T DK0637242T3 (da) 1992-04-21 1993-04-19 Midler til behandling af stofmisbrugslidelser
BR9306361A BR9306361A (pt) 1992-04-21 1993-04-19 Agentes para o tratamento de desordens resultantes do abuso de substâncias
AU40437/93A AU659941B2 (en) 1992-04-21 1993-04-19 Agents for treating substance abuse disorders
CA002118512A CA2118512C (en) 1992-04-21 1993-04-19 Agents for treating substance abuse disorders
JP51825193A JP3245642B2 (ja) 1992-04-21 1993-04-19 物質濫用疾患治療剤
RO94-01692A RO117150B1 (ro) 1992-04-21 1993-04-19 Metodă pentru tratamentul afecţiunilor provocate de abuzul faţă de drog sau altă substanţă
PCT/SE1993/000339 WO1993020821A1 (en) 1992-04-21 1993-04-19 Agents for treating substance abuse disorders
CZ942606A CZ281296B6 (cs) 1992-04-21 1993-04-19 Použití bisfenylalkylpiperazinů
US08/325,212 US5565455A (en) 1992-04-21 1993-04-19 Method for treating substance abuse disorders
HU9403020A HU223463B1 (hu) 1992-04-21 1993-04-19 Eljárás függőséget okozó szerek megvonása által okozott rendellenességek kezelésére szolgáló, piridil-biszfenilalkil-származék hatóanyagot tartalmazó gyógyászati készítmények előállítására
IL105449A IL105449A (en) 1992-04-21 1993-04-19 The use of bisphenylalkylpiperazines for the manufacture of medicines for the treatment of symptoms resulting from the misuse of certain substances and pharmaceutical preparations containing bisphenylalk
SK1269-94A SK279940B6 (sk) 1992-04-21 1993-04-19 Použitie bisfenylalkylpiperazínov
RU94045866A RU2126254C1 (ru) 1992-04-21 1993-04-19 Применение бисфенилалкилпиперазинов для лечения расстройств, вызванных злоупотреблением веществами, и способ лечения
UA94105949A UA27884C2 (uk) 1992-04-21 1993-04-19 Засіб для лікування розладів, викликаних зловживанням ліками та спосіб лікування або профілактики зазначеним засобом абстинентного синдрому
ZA932757A ZA932757B (en) 1992-04-21 1993-04-20 Agents for treating substance abuse disorders
PH46084A PH31051A (en) 1992-04-21 1993-04-21 Agents for treating substance abuse disorders.
BG99129A BG62154B1 (bg) 1992-04-21 1994-10-19 Средства за лечение на смущения, причинени от неправилнаупотреба на вещества
NO943977A NO308827B1 (no) 1992-04-21 1994-10-20 Midler til behandling av lidelser som stammer fra narkotikamisbruk
KR1019940703758A KR100321319B1 (ko) 1992-04-21 1994-10-21 물질남용장애를치료하는방법및제약학적조성물
EE9400398A EE02974B1 (et) 1992-04-21 1994-11-17 Bisfenüülalküülpiperasiinide kasutamine narkomaaniavastase ravimi valmistamiseks
GR990403117T GR3032030T3 (en) 1992-04-21 1999-12-02 Agents for treating substance abuse disorders.
NO20004169A NO318461B1 (no) 1992-04-21 2000-08-21 Midler til behandling av lidelser som stammer fra narkotikamisbruk

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9201239A SE9201239D0 (sv) 1992-04-21 1992-04-21 Agents for treating substance abuse disorders

Publications (1)

Publication Number Publication Date
SE9201239D0 true SE9201239D0 (sv) 1992-04-21

Family

ID=20386004

Family Applications (1)

Application Number Title Priority Date Filing Date
SE9201239A SE9201239D0 (sv) 1992-04-21 1992-04-21 Agents for treating substance abuse disorders

Country Status (26)

Country Link
US (1) US5565455A (ru)
EP (1) EP0637242B1 (ru)
JP (1) JP3245642B2 (ru)
KR (1) KR100321319B1 (ru)
AT (1) ATE184484T1 (ru)
AU (1) AU659941B2 (ru)
BG (1) BG62154B1 (ru)
BR (1) BR9306361A (ru)
CA (1) CA2118512C (ru)
CZ (1) CZ281296B6 (ru)
DE (1) DE69326459T2 (ru)
DK (1) DK0637242T3 (ru)
EE (1) EE02974B1 (ru)
ES (1) ES2139007T3 (ru)
GR (1) GR3032030T3 (ru)
HU (1) HU223463B1 (ru)
IL (1) IL105449A (ru)
NO (2) NO308827B1 (ru)
PH (1) PH31051A (ru)
RO (1) RO117150B1 (ru)
RU (1) RU2126254C1 (ru)
SE (1) SE9201239D0 (ru)
SK (1) SK279940B6 (ru)
UA (1) UA27884C2 (ru)
WO (1) WO1993020821A1 (ru)
ZA (1) ZA932757B (ru)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5316759A (en) * 1986-03-17 1994-05-31 Robert J. Schaap Agonist-antagonist combination to reduce the use of nicotine and other drugs
SE9201956D0 (sv) * 1992-06-25 1992-06-25 Kabi Pharmacia Ab Novel nicotinicacid esters
SE9601708D0 (sv) * 1996-05-06 1996-05-06 Pharmacia Ab Pyridyl- and pyrimidyl-piperazines in the treatment of substance abuse disorders
HU226859B1 (en) 1997-10-27 2009-12-28 Neurosearch As Phenyl- or heteroaryl-homopiperazines, their use and medicaments containing them
US6632823B1 (en) * 1997-12-22 2003-10-14 Merck & Co., Inc. Substituted pyridine compounds useful as modulators of acetylcholine receptors
US6358060B2 (en) 1998-09-03 2002-03-19 Jsr Llc Two-stage transmucosal medicine delivery system for symptom relief
US6344222B1 (en) 1998-09-03 2002-02-05 Jsr Llc Medicated chewing gum delivery system for nicotine
US6090780A (en) * 1999-04-07 2000-07-18 Chandon Prasad Histidyl-proline diketopiperazine and method of use
EP2422772A3 (en) 2002-09-20 2012-04-18 Alpharma, Inc. Sequestering subunit and related compositions and methods
HUE032156T2 (en) 2006-06-19 2017-09-28 Alpharma Pharmaceuticals Llc Pharmaceutical preparations
US8642016B2 (en) 2006-07-21 2014-02-04 Jsrnti, Llc Medicinal delivery system, and related methods
US8623418B2 (en) 2007-12-17 2014-01-07 Alpharma Pharmaceuticals Llc Pharmaceutical composition
BRPI1003506B1 (pt) 2010-09-24 2019-12-03 Ache Int Bvi Ltd composto alquil-piperazino-fenil-4(3h)quinazolinonas e uso do composto alquil-piperazino-fenil-4(3h)quinazolinonas associado aos receptores serotoninérgicos 5-ht1a e 5-ht2a

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2958694A (en) * 1959-06-22 1960-11-01 Janssen Paul Adriaan Jan 1-(aroylalkyl)-4-(2'-pyridyl) piperazines
US2985657A (en) * 1959-10-12 1961-05-23 Paul A J Janssen 1-(aroylalkyl)-4-heterocyclylpiperazines
US2979508A (en) * 1959-10-12 1961-04-11 Paul A J Janssen Heterocyclic derivatives of 1-phenyl-omega-(piperazine) alkanols
NO154582C (no) * 1978-10-20 1986-11-05 Ferrosan Ab Analogifremgangsmaate for fremstilling av terapeutisk aktive difenyl-dibutylpiperazinkarboksamider.
US4605655A (en) * 1984-03-06 1986-08-12 Bristol-Myers Company Antipsychotic 1-fluorophenylbutyl-4-(2-pyrimidinyl)piperazine derivatives
US4766215A (en) * 1987-02-27 1988-08-23 American Home Products Corporation Histamine H1 -receptor antagonists
SE8701375D0 (sv) * 1987-04-02 1987-04-02 Leo Ab Novel pyridyl- and pyrimidyl derivatives
US5217987A (en) * 1989-10-30 1993-06-08 Berger Stephen P Dopamine uptake inhibitors in reducing substance abuse and/or craving
SE9100860D0 (sv) * 1991-03-22 1991-03-22 Kabi Pharmacia Ab New use

Also Published As

Publication number Publication date
AU659941B2 (en) 1995-06-01
NO20004169D0 (no) 2000-08-21
SK279940B6 (sk) 1999-06-11
EP0637242A1 (en) 1995-02-08
IL105449A (en) 1998-02-22
SK126994A3 (en) 1995-07-11
DK0637242T3 (da) 2000-03-27
DE69326459T2 (de) 2000-03-23
ATE184484T1 (de) 1999-10-15
HU223463B1 (hu) 2004-07-28
WO1993020821A1 (en) 1993-10-28
RO117150B1 (ro) 2001-11-30
NO318461B1 (no) 2005-03-21
CA2118512C (en) 2004-07-27
ES2139007T3 (es) 2000-02-01
NO20004169L (no) 1994-10-20
BR9306361A (pt) 1998-06-30
NO308827B1 (no) 2000-11-06
RU94045866A (ru) 1996-10-20
KR950701221A (ko) 1995-03-23
KR100321319B1 (ko) 2002-07-27
RU2126254C1 (ru) 1999-02-20
UA27884C2 (uk) 2000-10-16
NO943977L (no) 1994-10-20
CZ281296B6 (cs) 1996-08-14
AU4043793A (en) 1993-11-18
NO943977D0 (no) 1994-10-20
JP3245642B2 (ja) 2002-01-15
HUT71420A (en) 1995-11-28
ZA932757B (en) 1993-10-28
BG62154B1 (bg) 1999-04-30
HU9403020D0 (en) 1994-12-28
EP0637242B1 (en) 1999-09-15
PH31051A (en) 1998-02-03
CA2118512A1 (en) 1993-10-28
CZ260694A3 (en) 1995-09-13
DE69326459D1 (de) 1999-10-21
EE02974B1 (et) 1997-04-15
BG99129A (bg) 1995-08-28
US5565455A (en) 1996-10-15
IL105449A0 (en) 1993-08-18
GR3032030T3 (en) 2000-03-31
JPH08503449A (ja) 1996-04-16

Similar Documents

Publication Publication Date Title
SE9201239D0 (sv) Agents for treating substance abuse disorders
DK0538422T3 (da) Hidtil ukendt anvendelse af diphenylbutyl-piperazincarboxamider til behandling af stofmisbrugslidelser
EA199700119A1 (ru) Соединения, оказывающие эффекты на системы, связанные с серотонином
DE69613113T2 (de) Unhabhängige vorrichtung zur transdermalen verabreichung von medikamenten
FI964332A0 (fi) Eräiden metaanibisfosfonihappojohdannaisten käyttö proteesin löystymisen ja proteesin vaelluksen estämiseen
Levine et al. The effect of centrally administered naloxone on deprivation and drug-induced feeding
DE69617729D1 (de) Verwendung von antimineralcorticoidverbindungen gegen das drogenentzugssyndrom
DE3778008D1 (de) Ketonderivate als arzneimittel zur behandlung oder vorbeugung des entzugssyndromes.
NO943293L (no) Anvendelse av et medikament ved avvenning mot röyk
Matalon et al. Chronic use of hypnotics in a family practice—patients' reluctance to stop treatment
KR890011572A (ko) 정신 기능을 증진시키는 방법
ATE147980T1 (de) Verwendung von 3,5-diamino-6-(2,3-dichlorophenyl)-1,2,4,-triaz nisethionat zur behandlung und vorbeugung von drogenabhaengigkeit,-toleranz und- sensibilisierung
Jeanmonod et al. The drug dependent prisoner: Medical treatment and its limits
Goswami et al. Pentazocine Detoxification: A Focus on Clonidine
MX9703032A (es) Nuevas aplicaciones del 5-etoxicarbonil-2,4,6-trimetil-1,4-dihidropiridina-3-carboxi lato de 2-[n-(1,2-benzisotiazolil-3(2h) ona-1,1-dioxido]etilo.